Aclarion Inc (ACON) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aclarion Inc (ACON) has a cash flow conversion efficiency ratio of -0.093x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.16 Million) by net assets ($12.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Aclarion Inc (ACON) market capitalisation for the company's overall valuation and market capitalisation.
Aclarion Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Aclarion Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aclarion Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aclarion Inc ranked by their cash flow conversion efficiency. See ACON operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bohra Industries Limited
NSE:BOHRAIND
|
0.009x |
|
GEMINA LABS LTD
F:8I7
|
-0.007x |
|
CanadaBis Capital Inc
V:CANB
|
0.056x |
|
Strategic Equity Capital Closed Fund
LSE:SEC
|
0.001x |
|
Ngenic AB
ST:NGENIC
|
0.592x |
|
CBEYOND
F:C5B
|
0.724x |
|
McLaren Resources Inc
F:3ML
|
0.398x |
|
Central China Real Estate Limited
F:AJ5
|
-0.088x |
Annual Cash Flow Conversion Efficiency for Aclarion Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Aclarion Inc from 2019 to 2024. View ACON live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $970.06K | $-5.27 Million | -5.434x | -208.48% |
| 2023-12-31 | $-728.00K | $-3.65 Million | 5.010x | +309.84% |
| 2022-12-31 | $2.23 Million | $-5.31 Million | -2.387x | -682.05% |
| 2021-12-31 | $-5.73 Million | $-2.35 Million | 0.410x | +61.97% |
| 2020-12-31 | $-7.08 Million | $-1.79 Million | 0.253x | -89.67% |
| 2019-12-31 | $-1.70 Million | $-4.17 Million | 2.451x | -- |
About Aclarion Inc
Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom softwa… Read more